
FDA probes deaths of boys taking Sarepta Duchenne drug
REGULATION FDA probes deaths of boys taking Sarepta Duchenne drug The FDA said yesterday that it is investigating the deaths from liver failure of two non-ambulatory boys with Duchenne muscular dystrophy who were treated with Sarepta Therapeutics’ gene …